` 600079 (Humanwell Healthcare Group Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

600079
vs
S
Shanghai Composite

Over the past 12 months, Humanwell Healthcare Group Co Ltd has underperformed Shanghai Composite, delivering a return of -12% compared to the Shanghai Composite's +28% growth.

Stocks Performance
600079 vs Shanghai Composite

Loading
600079
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
600079 vs Shanghai Composite

Loading
600079
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
600079 vs Shanghai Composite

Loading
600079
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Humanwell Healthcare Group Co Ltd vs Peers

Shanghai Composite
600079
JEF
JNJ
4312
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Humanwell Healthcare Group Co Ltd
Glance View

Market Cap
30B CNY
Industry
Pharmaceuticals

In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.

Intrinsic Value
31.56 CNY
Undervaluation 42%
Intrinsic Value
Price
Back to Top